Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article
Effect of Docosahexaenoic Acid Supplementation on Glucose Tolerance and Markers of Inflammation in Overweight/Obese Pregnant Women: A Double-blind, Randomized, Controlled Trial
| Debra A Krummel1*, Alison Baker Kuhn1, Alison M Cassin1, Sarah L Davis1, Lindsay E Walker1, Jane C Khoury2 and Theresa L Powell3 | |
| 1Department of Nutritional Sciences, University of Cincinnati, Cincinnati, Ohio, USA | |
| 2Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA | |
| 3Department of Pediatrics, Section for Neonatology, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA | |
| Corresponding Author : | Debra A Krummel Department of Nutritional Sciences University of Cincinnati, Cincinnati, Ohio, USA Tel: 513-460-1509 Fax: 513-558- 7500 E-mail: debra.krummel@uc.edu |
| Received: November 26, 2015; Accepted: January 20, 2016; Published: January 27, 2016 | |
| Citation: Krummel DA, Kuhn AB, Cassin AM, Davis SL, Walker LE, et al. (2016) Effect of Docosahexaenoic Acid Supplementation on Glucose Tolerance and Markers of Inflammation in Overweight/Obese Pregnant Women: A Double-blind, Randomized, Controlled Trial. J Preg Child Health 2:212. doi:10.4172/2376-127X.1000212 | |
| Copyright: © 2016 Krummel DA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
Abstract
Background: Obese, pregnant women have exacerbated inflammation and insulin resistance that put them and their fetus at risk for adverse prenatal outcomes and future risk of cardiometabolic disease. Our objective was to determine the effects of 10 weeks of docosahexaenoic acid (DHA) supplementation on glucose tolerance and markers of inflammation in healthy, overweight/obese, pregnant women. Method: Using a randomized, double-blind, placebo-controlled trial, 60 women, with a pregravid body mass index ≥ 25 consumed placebo or DHA (800 mg DHA, algal oil) capsules for 10 weeks from 26 to 36 weeks gestation. Erythrocyte DHA (EDHA), plasma tumor necrosis factor (TNF-α), and interleukin 6 (IL-6) were measured at 36 weeks. Homeostatic model assessment of insulin resistance (HOMA-IR), beta cell function (HOMA-B %), and insulin sensitivity (HOMA-S %) were calculated from glucose and insulin measurements during a 2-hour meal challenge at 36 weeks. Data were analyzed using SPSS (version 22) and SAS (version 9.3). Results: After supplementation, the mean EDHA increased by 25% and decreased by 14% in the DHA or placebo group, respectively (P<0.0005). None of the markers of glucose metabolism were significantly different between treatment groups. There was a significant time by group interaction for TNF-α (P=0.03, η2=0.08) with DHA lessening the rise seen in TNF-α between 26 and 36 weeks gestation. Conclusion: DHA supplementation from 26 to 36 weeks of gestation improved the inflammatory environment of overweight/obese pregnant women. Glucose tolerance homeostasis was not significantly different between groups.
